期刊
EXPERT OPINION ON DRUG SAFETY
卷 14, 期 8, 页码 1201-1211出版社
TAYLOR & FRANCIS LTD
DOI: 10.1517/14740338.2015.1053458
关键词
aromatase inhibitors; arthralgia; bone; breast cancer; cognition; hot flashes; lipids; tamoxifen; vulvovaginal atrophy
Introduction: Aromatase inhibitor (AI) therapy is the current preferred choice of endocrine therapy in postmenopausal estrogen receptor-positive breast cancer patients thanks to their improved effectiveness compared to tamoxifen. Despite the absence of increased endometrial pathology and deep venous thrombosis seen in tamoxifen-users, the safety profile of AIs consists of a variety of bothersome side effects negatively influencing daily functioning. Areas covered: Besides the well-known adverse effects on joints and bone and the vasomotor system, more neglected and latent toxicity like cognitive problems and vulvovaginal atrophy will be discussed. Concern has been raised in terms of increased risk of fractures and cardiovascular events with chronic AI use. Expert opinion: Placebo-controlled long-term studies carefully monitoring these adverse events, together with more extensive research in the etiologies, are warranted.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据